Ronan Depoortère

Introduction Click to copy section linkSection link copied! NLX-112 is a first-in-class, highly selective, and potent 5-HT 1A receptor agonist that effectively counteracts dyskinesia and abnormal involuntary movements in levodopa-primed rodent and primate models of Parkinson’s disease (PD). (1−4) Moreover, a recent double-blind, placebo-controlled Phase 2A clinical trial demonstrated robust antidyskinetic and antiparkinsonian efficacy of NLX-112 in PD patients.

Chronic pain is a widespread pathology that, in addition to causing personal suffering, presents a major public health challenge and substantial economic burden due to direct health care costs and lost productivity. Thus, in the USA alone, the annual cost of pain disorders is estimated at between $560 and $635 billion (2010 equiv US$), far above the costs of other main pathologies.